BidaskClub upgraded shares of Tocagen (NASDAQ:TOCA) from a hold rating to a buy rating in a research report released on Tuesday.
Other equities research analysts have also recently issued reports about the company. ValuEngine upgraded Tocagen from a hold rating to a buy rating in a report on Thursday, September 27th. Chardan Capital assumed coverage on Tocagen in a report on Thursday, August 30th. They issued a buy rating and a $30.00 price objective on the stock. HC Wainwright set a $15.00 price objective on Tocagen and gave the stock a buy rating in a report on Monday, November 12th. B. Riley lifted their price objective on Tocagen from $15.00 to $22.00 and gave the stock a buy rating in a report on Thursday, September 20th. Finally, Zacks Investment Research upgraded Tocagen from a sell rating to a hold rating in a report on Saturday, November 10th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The stock currently has an average rating of Buy and an average target price of $20.83.
TOCA stock opened at $13.26 on Tuesday. The company has a current ratio of 5.83, a quick ratio of 5.83 and a debt-to-equity ratio of 0.55. Tocagen has a 12-month low of $7.52 and a 12-month high of $15.80.
Institutional investors have recently modified their holdings of the company. Beaumont Financial Partners LLC acquired a new position in shares of Tocagen during the 3rd quarter worth approximately $212,000. Raymond James & Associates acquired a new position in shares of Tocagen during the 2nd quarter worth approximately $142,000. Citadel Advisors LLC acquired a new position in shares of Tocagen during the 3rd quarter worth approximately $251,000. First Republic Investment Management Inc. acquired a new position in shares of Tocagen during the 2nd quarter worth approximately $170,000. Finally, Dimensional Fund Advisors LP acquired a new position in shares of Tocagen during the 3rd quarter worth approximately $481,000. Institutional investors and hedge funds own 29.68% of the company’s stock.
Tocagen Inc, a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells.
Featured Story: What does relative strength index mean?
Receive News & Ratings for Tocagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen and related companies with MarketBeat.com's FREE daily email newsletter.